TruNativ, a company focused on developing new generation ingredient concepts for health and wellbeing, has closed a $30.0M Series B funding round. The capital infusion comes from OrbiMed, backing the company's research into areas like body maintenance, cognitive performance, and immunity.
The company aims to address a broader shift in health, moving beyond temporary deficiencies to continuous control of wellbeing for people of all ages. TruNativ's work in Phyto active properties and inflammation seeks to open new paths in this evolving landscape.













.png&w=3840&q=75)

